CORBF vs. CSTL, CELC, PSNL, FTRE, AIRS, TOI, VMD, XGN, DCGO, and KDLY
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Castle Biosciences (CSTL), Celcuity (CELC), Personalis (PSNL), Fortrea (FTRE), AirSculpt Technologies (AIRS), Oncology Institute (TOI), Viemed Healthcare (VMD), Exagen (XGN), DocGo (DCGO), and Kindly MD (KDLY). These companies are all part of the "healthcare" industry.
Global Cord Blood vs. Its Competitors
Global Cord Blood (NYSE:CORBF) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
Global Cord Blood has a beta of -0.66, meaning that its stock price is 166% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Castle Biosciences received 95 more outperform votes than Global Cord Blood when rated by MarketBeat users.
Global Cord Blood has higher earnings, but lower revenue than Castle Biosciences.
Castle Biosciences has a consensus target price of $37.00, indicating a potential upside of 96.60%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Global Cord Blood.
In the previous week, Castle Biosciences had 2 more articles in the media than Global Cord Blood. MarketBeat recorded 2 mentions for Castle Biosciences and 0 mentions for Global Cord Blood. Castle Biosciences' average media sentiment score of 1.09 beat Global Cord Blood's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media.
92.6% of Castle Biosciences shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 6.5% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Castle Biosciences has a net margin of 1.95% compared to Global Cord Blood's net margin of 0.00%. Castle Biosciences' return on equity of 1.47% beat Global Cord Blood's return on equity.
Summary
Castle Biosciences beats Global Cord Blood on 14 of the 15 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy CORBF Stock Free CORBF Stock Alerts